Loading clinical trials...
Loading clinical trials...
This phase I study will evaluate the feasibility and toxicity of weekly bortezomib in the treatment of relapsed or refractory multiple Myeloma and determine whether a twice-weekly schedule of bortezom...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
SCRI Development Innovations, LLC
Collaborators
NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma
NCT06215118 · Multiple Myeloma
NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT06057402 · Multiple Myeloma
Florida Cancer Specialists
Fort Myers, Florida
Tennessee Oncology, PLLC
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions